Oncternal Therapeutics To Sell Zilovertamab And ONCT-808 Programs To Hoola Therapeutics

Oncternal Therapeutics (ONCT) has divested its key zilovertamab and ONCT-808 programs to Ho'ola Therapeutics for an initial $3.0 million, with potential milestone payments up to $65.0 million tied to development, regulatory, and sales achievements. This transaction, completed on June 27, 2025, signals Oncternal's strategic winddown, evidenced by the appointment of Craig Jalbert, an expert in company dissolution, as its sole executive and board member, tasked with overseeing the liquidation of operations and managing any future milestone receipts.

Analysis

Oncternal Therapeutics (ONCT) is effectively ceasing operations following the sale of its primary assets, the zilovertamab and ONCT-808 programs, to Ho'ola Therapeutics. The transaction provides a modest $3.0 million in upfront cash, with the majority of the deal's potential value, up to $65.0 million, being highly contingent on future development, regulatory, and sales milestones. The definitive nature of this event is underscored by the subsequent corporate restructuring: the entire management team and board have resigned, replaced by a single appointee, Craig Jalbert, whose professional experience is explicitly in overseeing corporate dissolutions. His mandate is to manage the winddown of Oncternal's operations and distribute remaining cash and any future milestone proceeds. The strongly negative sentiment score of -0.8 accurately reflects that the company is no longer an ongoing biopharmaceutical concern but has transitioned into a liquidating shell entity.

Key Decisions for Investors

• Investors should recognize that Oncternal is undergoing a corporate dissolution and will no longer operate as a research and development entity; the stock now represents a claim on distributable cash and potential long-term, highly speculative milestone payments.
• The valuation of ONCT equity is now primarily tied to its net liquidation value plus the heavily discounted, probabilistic value of the $65.0 million in milestones, which depend entirely on the future success of a separate company, Ho'ola Therapeutics.
• Considering the company's liquidation status and the uncertain nature of future payouts, any remaining investment constitutes a long-term, high-risk bet on the divested assets achieving significant clinical and commercial success under new ownership.